A Phase 1 Dosing Study of Ruxolitinib in Children with Relapsed or Refractory Solid tumors, Leukemias, or Myeloproliferative Neoplasms: A Children's Oncology Group Phase 1 Consortium Study (ADVL1011)

BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations. PROCEDURE: A phase 1 trial of ruxolitinib was performed to determine the maximum-tolerated or recommended phase 2 dose, dose-limiting toxicities (DLTs), pharmacokinetics (P...

全面介紹

Na minha lista:
書目詳細資料
發表在:Pediatr Blood Cancer
Main Authors: Loh, Mignon L., Tasian, Sarah K., Rabin, Karen R., Brown, Patrick, Magoon, Daniel, Reid, Joel M., Chen, Xuejun, Ahern, Charlotte H., Weigel, Brenda J., Blaney, Susan M.
格式: Artigo
語言:Inglês
出版: 2015
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546537/
https://ncbi.nlm.nih.gov/pubmed/25976292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25575
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍